Product Description: Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma[1][2][3][4].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Mizuno T, et, al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci Rep. 2020 Jul 10;10(1):11476. /[2]Hu C, et al. Characterization of a potent and selective A2aR monoclonal antibody antagonist for the treatment of cancer[J]. Cancer Research, 2022, 82(12_Supplement): 3437-3437./[3]Dias JNR, et al. Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy. Sci Rep. 2022 Feb 17;12(1):2678./[4]Ferrari F, et al. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. Eur J Pharmacol. 2016 Dec 15;793:1-13.
CAS Number: 1608112-78-2
Molecular Weight: N/A
Compound Purity: 99.08
Research Area: Cancer
Solubility: H2O
Target: Adenosine Receptor;CD20
English
Deutsch
